RT info:eu-repo/semantics/article
T1 Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome
A1 Morales, Albert
A1 Rojo Rello, Silvia
A1 Cristóbal, Helena
A1 Fiz López, Aida
A1 Arribas Rodríguez, Elisa
A1 Mari, Montserrat
A1 Tutusaus, Anna
A1 Cal Sabater, Paloma de la
A1 Nicolaes, Gerry
A1 Ortiz Pérez, José T.
A1 Bernardo Ordiz, David
A1 García de Frutos, Pablo
K1 COVID-19 (Enfermedad)
K1 Viral infections
K1 Infecciones virales
K1 Immune responses
K1 Respuestas inmunes
K1 Inmunotrombosis
K1 Vitamin K
K1 Vitamina K
AB Background: Growth arrest-specific factor 6 (GAS6) and the Tyro3, AXL, and MERTK (TAM) receptors counterbalance pro-inflammatory responses. AXL is a candidate receptor for SARS-CoV-2, particularly in the respiratory system, and the GAS6/AXL axis is targeted in current clinical trials against COVID-19. However, GAS6 and TAMs have not been evaluated in COVID-19 patients at emergency admission. Methods: Plasma GAS6, AXL, and MERTK were analyzed in 132 patients consecutively admitted to the emergency ward during the first peak of COVID-19. Results: GAS6 levels were higher in the SARS-CoV-2-positive patients, increasing progressively with the severity of the disease. Patients with initial GAS6 at the highest quartile had the worst outcome, with a 3-month survival of 65%, compared to a 90% survival for the rest. Soluble AXL exhibited higher plasma concentration in deceased patients, without significant differences in MERTK among SARS-CoV-2-positive groups. GAS6 mRNA was mainly expressed in alveolar cells and AXL in airway macrophages. Remarkably, THP-1 human macrophage differentiation neatly induces AXL, and its inhibition (bemcentinib) reduced cytokine production in human macrophages after LPS challenge. Conclusions: Plasma GAS6 and AXL levels reflect COVID-19 severity and could be early markers of disease prognosis, supporting a relevant role of the GAS6/AXL system in the immune response in COVID-19.
PB MDPI
SN 2227-9059
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/51573
UL https://uvadoc.uva.es/handle/10324/51573
LA eng
NO Biomedicines, 2021, vol. 9, n. 4, 335
NO Producción Científica
DS UVaDOC
RD 07-ago-2024